197 related articles for article (PubMed ID: 19786980)
1. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients.
Khrunin AV; Moisseev A; Gorbunova V; Limborska S
Pharmacogenomics J; 2010 Feb; 10(1):54-61. PubMed ID: 19786980
[TBL] [Abstract][Full Text] [Related]
2. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival.
Beeghly A; Katsaros D; Chen H; Fracchioli S; Zhang Y; Massobrio M; Risch H; Jones B; Yu H
Gynecol Oncol; 2006 Feb; 100(2):330-7. PubMed ID: 16199080
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.
Liu B; Wei J; Zou Z; Qian X; Nakamura T; Zhang W; Ding Y; Feng J; Yu L
Eur J Hum Genet; 2007 Oct; 15(10):1049-53. PubMed ID: 17593927
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
[TBL] [Abstract][Full Text] [Related]
6. Association of glutathione S-transferase GSTM1 and GSTT1 null genotypes with clinical outcome in epithelial ovarian cancer.
Howells RE; Redman CW; Dhar KK; Sarhanis P; Musgrove C; Jones PW; Alldersea J; Fryer AA; Hoban PR; Strange RC
Clin Cancer Res; 1998 Oct; 4(10):2439-45. PubMed ID: 9796976
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer.
Holley SL; Rajagopal R; Hoban PR; Deakin M; Fawole AS; Elder JB; Elder J; Smith V; Strange RC; Fryer AA
Int J Oncol; 2006 Jan; 28(1):231-6. PubMed ID: 16328000
[TBL] [Abstract][Full Text] [Related]
8. ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
Rumiato E; Cavallin F; Boldrin E; Cagol M; Alfieri R; Basso D; Castoro C; Ancona E; Amadori A; Ruol A; Saggioro D
Pharmacogenet Genomics; 2013 Nov; 23(11):597-604. PubMed ID: 23962907
[TBL] [Abstract][Full Text] [Related]
9. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
10. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in metabolic GSTP1 and DNA-repair XRCC1 genes with an increased risk of DNA damage in pesticide-exposed fruit growers.
Wong RH; Chang SY; Ho SW; Huang PL; Liu YJ; Chen YC; Yeh YH; Lee HS
Mutat Res; 2008 Jul; 654(2):168-75. PubMed ID: 18603015
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.
Oldenburg J; Kraggerud SM; Cvancarova M; Lothe RA; Fossa SD
J Clin Oncol; 2007 Feb; 25(6):708-14. PubMed ID: 17228018
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
14. Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
Chen YC; Tzeng CH; Chen PM; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer Sci; 2010 Feb; 101(2):530-5. PubMed ID: 19922504
[TBL] [Abstract][Full Text] [Related]
15. Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients.
Saldivar JS; Lu KH; Liang D; Gu J; Huang M; Vlastos AT; Follen M; Wu X
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S223-9. PubMed ID: 17825393
[TBL] [Abstract][Full Text] [Related]
16. Functional glutathione S-transferase genotypes among testicular germ cell tumor survivors: associations with primary and post-chemotherapy tumor histology.
Kraggerud SM; Oldenburg J; Alnaes GI; Berg M; Kristensen VN; Fossa SD; Lothe RA
Pharmacogenet Genomics; 2009 Oct; 19(10):751-9. PubMed ID: 19741569
[TBL] [Abstract][Full Text] [Related]
17. [Association of polymorphisms in glutathione-S-transferase and DNA repair genes with ovarian cancer risk in the Russian population].
Khokhrin DV; Khrunin AV; Moiseev AA; Gorbunov VA; Limborskaia SA
Genetika; 2012 Jul; 48(7):901-4. PubMed ID: 22988779
[TBL] [Abstract][Full Text] [Related]
18. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins.
Khrunin A; Ivanova F; Moisseev A; Khokhrin D; Sleptsova Y; Gorbunova V; Limborska S
Pharmacogenomics; 2012 Jan; 13(2):171-8. PubMed ID: 22188361
[TBL] [Abstract][Full Text] [Related]
20. Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk.
Miller DP; Liu G; De Vivo I; Lynch TJ; Wain JC; Su L; Christiani DC
Cancer Res; 2002 May; 62(10):2819-23. PubMed ID: 12019159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
